<DOC>
	<DOCNO>NCT01992549</DOCNO>
	<brief_summary>The purpose study collect long-term data inhibitor development rate Human-cl rhFVIII previously untreated patient severe Hemophilia A .</brief_summary>
	<brief_title>Study Investigate Immunogenicity , Efficacy Safety Treatment With Human-cl rhFVIII</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>1 . Patients complete GENA05 accordance study protocol 1 . Severe liver kidney disease 2 . Concomitant treatment systemic immunosuppressive drug ; 3 . Other FVIII concentrate Humancl rhFVIII receive completion visit GENA05 start GENA15 ( except emergency case ) .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>